1. Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series
- Author
-
Chenjun Guo, Ping Wang, Shaobo Zhang, Qilin Cheng, Qiong Zhang, Nan Ma, and Yangjun Li
- Subjects
Graves’ ophthalmopathy ,Ocular myasthenia gravis ,Tocilizumab ,GO-QoL ,MG-ADL ,CAS ,Ophthalmology ,RE1-994 - Abstract
Abstract Purpose To highlight the safety and efficacy of tocilizumab (TCZ) in Graves’ ophthalmopathy (GO) combined with ocular myasthenia gravis (OMG) patients refractory to steroids and cholinesterase inhibitor (CEI). Methods This was retrospective case series. We reviewed the health records of patients with GO combined with OMG, ten of whom were refractory to corticosteroids and CEI treatment and received intravenous injection of TCZ. Ten patients were treated with four injections of TCZ (intravenously, 8 mg per kilogram of body weight, once a month). We analyzed the efficacy and safety of TCZ treatment for this subset of patients with GO and OMG. Results The main outcomes including quality of life questionnaire in Graves’ orbitopathy (GO-QoL) score, Clinical Activity Score (CAS), Myasthenia Gravis Activities of Daily Living profile (MG-ADL) score, proptosis, diplopia and ptosis were assessed at 3 time points: “Baseline” (before the TCZ injection), “4th month” (after fourth time TCZ injection), “Follow up” (Last follow-up). Comparing parameters at 4th month vs. at baseline, all indicators improved at 4th month including GO-QoL score of visual functioning subscale (82.29 ± 13.71 vs. 35.98 ± 20.66, P
- Published
- 2024
- Full Text
- View/download PDF